Johnson & Johnson Extends Royal Dividend Status With 3.1% Boost
By Colin Kellaher
Johnson & Johnson's board has raised the quarterly dividend by 3.1%, to $1.34 from $1.30, making it 64 straight years that the healthcare giant has boosted its payout.
The new dividend, equal to $5.36 a year, represents an annual yield of about 2.25% based on Monday's closing price of $237.96, up from 2.19%.
With the increase, J&J maintains its place in the S&P 500 Dividend Aristocrats Index, whose 69 members have paid a higher dividend for at least 25 straight years.
The increase also keeps J&J's spot on the smaller list of dividend kings--those who have raised their dividends annually for at least a half century. That group currently counts 57 members, according to website Sure Dividend.
The New Brunswick, N.J., company on Tuesday said the increased dividend is payable June 9 to shareholders of record May 26.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 14, 2026 06:42 ET (10:42 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
What 7 Key Market Indicators Are Telling Investors Right Now
United States